HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Extended structure-activity study of thienopyrimidine-based EGFR inhibitors with evaluation of drug-like properties.

Abstract
Thieno[2,3-d]pyrimidines are attractive derivatives for cancer treatment, among others through regulation of the epidermal growth factor receptor tyrosine kinase (EGFR-TK). In an extended SAR study, 44 new compounds of this class have been evaluated as inhibitors, while simultaneously focussing on ADME properties. Through the application of bioisosters, hybrid structures, solubilizing tails, and a combination approach several successful alterations in terms of activity and physiochemical properties were accomplished. Compounds based on benzylamines were found superior to aniline hybrid structures with respect to activity and ADME profile. Exploration of the former class revealed meta- and para amides as favourable 6-aryl substituents, contributing to an increase in activity and acting as a linker for solubilizing tails. Next, combinations of activity-inducing groups on the same scaffold resulted in new drug candidates. Compounds containing 6-aryls with the (2-(dimethylamino)ethyl)carbamoyl substituent were found equipotent to Erlotinib. Compared to this commercial drug, improved solubility and metabolic stability were observed. However, the thieno[2,3-d]pyrimidines with a solubilizing tail was by Caco-2 experiments found to have permeability issues, making further drug development difficult. Selected compounds were further analysed for toxicity and teratogenicity in zebrafish embryos. Two thienopyrimidines were both found to be less lethal than Erlotinib and to perform as well in terms of teratogenicity. Finally, the most promising thienopyrimidine drug was evaluated in a panel of human cancer cell lines, showing a clear potential for thienopyrimidines as anti-cancer agents.
AuthorsSteffen Bugge, Audun Formo Buene, Nathalie Jurisch-Yaksi, Ingri Ullestad Moen, Ellen Martine Skjønsfjell, Eirik Sundby, Bård Helge Hoff
JournalEuropean journal of medicinal chemistry (Eur J Med Chem) Vol. 107 Pg. 255-74 (Jan 01 2016) ISSN: 1768-3254 [Electronic] France
PMID26599532 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier Masson SAS. All rights reserved.
Chemical References
  • Aniline Compounds
  • Antineoplastic Agents
  • Benzylamines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • thienopyrimidine
  • benzylamine
  • EGFR protein, human
  • ErbB Receptors
  • aniline
Topics
  • Aniline Compounds (chemistry)
  • Animals
  • Antineoplastic Agents (chemistry, pharmacokinetics, pharmacology)
  • Benzylamines (chemistry)
  • Drug Design
  • Drug Evaluation, Preclinical (methods)
  • Embryo, Nonmammalian (drug effects)
  • ErbB Receptors (antagonists & inhibitors, metabolism)
  • Humans
  • Protein Kinase Inhibitors (chemistry, pharmacokinetics, pharmacology)
  • Pyrimidines (chemistry)
  • Structure-Activity Relationship
  • Toxicity Tests
  • Zebrafish (embryology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: